Rokit Healthcare

Rokit Healthcare FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Rokit Healthcare (376900.KQ) as of Nov 1, 2026 is 624.42 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 67.99 % — a change of 818.45% (higher).

FCF Conversion

624.42 %

YoY

818.45%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Rokit Healthcare is 2025 624.42 % . FCF Conversion Rate (FCF/EBITDA) of Rokit Healthcare was 2024 67.99 % . It decreases by 818.45% higher compared to the previous year.

The Rokit Healthcare FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
-362.90 KRW
Jan 1, 2023
-25.38 KRW
Jan 1, 2024
67.99 KRW
Jan 1, 2025
624.42 KRW
The Rokit Healthcare FCF Conversion history
YEARFCF ConversionYoY
624.42 %+818.45%
67.99 %-367.90%
-25.38 %-93.01%
-362.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rokit Healthcare Stock analysis

What does Rokit Healthcare do? Rokit Healthcare Inc develops and sells medical supplies and pharmaceutical products through its AI organ regeneration platform. The company offers three core services: medical 3-dimensional (3D) bioprinting using biocompatible materials, AI automated precision modeling for affected areas, and disposable medical device kits for assembly and disassembly. These services target healthcare providers and medical institutions seeking advanced solutions for organ regeneration and precision medical procedures. The firm also engages in manufacturing, development, sales, wholesale, and retail of medical devices, supporting both domestic and international markets. The medical 3D bioprinting service creates 3D structures with biomaterials, while the AI automated precision modeling service uses artificial intelligence to model affected areas accurately. Disposable medical device kits are sterile and designed for direct assembly and disassembly, catering to hospitals and clinics requiring efficient, sterile medical tools. Rokit Healthcare Inc's business model focuses on delivering integrated AI-driven medical solutions that combine bioprinting, modeling, and disposable device kits to enhance patient care and surgical precision. Rokit Healthcare Inc's primary revenue streams come from the sale of its AI organ regeneration platform services and the associated medical devices. Healthcare providers and medical institutions purchase these services and products to improve treatment outcomes and streamline surgical processes. The company's manufacturing and distribution activities in medical devices further contribute to its revenue, with a strong emphasis on innovation in AI and bioprinting technologies to maintain market competitiveness. Rokit Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rokit Healthcare stock

FCF Conversion Rate (FCF/EBITDA) of Rokit Healthcare is 624.42 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Rokit Healthcare changed from 67.99 % to 624.42 %, representing a 818.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Rokit Healthcare since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Rokit Healthcare with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Rokit Healthcare

All Key Metrics — Rokit Healthcare